Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for ...

NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...

Mines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...

Mainz Biomed Announces Stock Split. BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...

Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...

Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...

The Nasdaq Hearings Panel has given Psyence Biomed until December 31, 2024, to comply with the minimum bid price, market value of publicly held shares, and stockholders' equity requirements. During ...

During the Nasdaq Listing Qualifications Hearing, Psyence Biomed presented a comprehensive plan to regain and maintain compliance with the exchange’s continued listing requirements, including ...

A new report released from the National Academies of Sciences, Engineering, and Medicine Health and Medicine Division addresses the responsible use of race and ethnicity in biomedical research and is ...